Skip to main content
Erschienen in: Medical Oncology 2/2012

01.06.2012 | Original Paper

Accuracy of GFR estimation by the Cockroft and Gault, MDRD, and Wright equations in Oncology patients with renal impairment

verfasst von: O. O. Faluyi, S. P. Masinghe, R. L. Hayward, S. Clive

Erschienen in: Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Estimation of renal function is crucial to guidance of systemic chemotherapy. With stable creatinine levels, the glomerular filtration rate (GFR) is often estimated from a single measurement of serum creatinine. We compared accuracy of the Cockroft and Gault (C&G), modifying diet in renal diseases (MDRD) and Wright estimates in Oncology patients with renal impairment. Analysis was carried out on the basis of monodentate platinum treatment as the nephrotoxic mechanism of these drugs may affect accuracy of these estimates. Sixty-two consecutive patients with stable creatinine levels who had isotopic GFR measurement of ≤ 60 ml min−1 at a regional cancer center were reviewed. Twenty-nine were on monodentate platinum treatment. Isotopic GFR was compared with estimated GFR by the three equations. We defined three categories of estimate based on the fractional difference from isotopic GFR: ‘perfect’ (< 10%), ‘reasonable’ (≥ 10% but < 30%) and ‘poor’ (≥ 30%). There was a trend toward provision of more perfect estimates by the MDRD equation particularly in patients on monodentate platinum treatment. Similar numbers had poor estimates from either of these equations, particularly at extremes of body weight. The MDRD formula may be the most accurate of these equations in Oncology patients with renal impairment, particularly with monodentate platinum treatment.
Literatur
1.
Zurück zum Zitat Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.PubMedCrossRef Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.PubMedCrossRef
2.
Zurück zum Zitat Wright, et al. Estimation of glomerular filtration rate in cancer patients. Brit J Cancer. 2001;84(4):452–9.PubMedCrossRef Wright, et al. Estimation of glomerular filtration rate in cancer patients. Brit J Cancer. 2001;84(4):452–9.PubMedCrossRef
3.
Zurück zum Zitat Kvale, et al. History of cancer and mortality in community-dwelling older adults. Cancer Epidemiol. 2010 [Epub: Aug 2010]. Kvale, et al. History of cancer and mortality in community-dwelling older adults. Cancer Epidemiol. 2010 [Epub: Aug 2010].
4.
Zurück zum Zitat Launay-Vacher, et al. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit. 2004;10(5):209–12. Launay-Vacher, et al. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit. 2004;10(5):209–12.
5.
Zurück zum Zitat Levey, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.PubMed Levey, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.PubMed
6.
Zurück zum Zitat Stevens, et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol. 2007;18(10):2749–57.PubMedCrossRef Stevens, et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol. 2007;18(10):2749–57.PubMedCrossRef
7.
Zurück zum Zitat Barraclough, et al. Estimation of renal function – what is appropriate in cancer patients? Clin Oncol. 2008;20(10):721–6.CrossRef Barraclough, et al. Estimation of renal function – what is appropriate in cancer patients? Clin Oncol. 2008;20(10):721–6.CrossRef
8.
Zurück zum Zitat Harland, et al. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res. 1984;44(4):1693–7.PubMed Harland, et al. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res. 1984;44(4):1693–7.PubMed
9.
Zurück zum Zitat de Lemos, et al. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies. Gynecol Oncol. 2006;103(3):1063–9.PubMedCrossRef de Lemos, et al. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies. Gynecol Oncol. 2006;103(3):1063–9.PubMedCrossRef
10.
Zurück zum Zitat Nonclercq, et al. Tissue injury and repair in the rat kidney after exposure to cisplatin or carboplatin. Exp Mol Pathol. 1989;51(2):123–40.PubMedCrossRef Nonclercq, et al. Tissue injury and repair in the rat kidney after exposure to cisplatin or carboplatin. Exp Mol Pathol. 1989;51(2):123–40.PubMedCrossRef
11.
Zurück zum Zitat Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5(5):303–11.PubMed Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5(5):303–11.PubMed
12.
Zurück zum Zitat Waller DG, Keast CM, Fleming JS, Ackery DM. Measurement of glomerular filtration rate with technetium-99m DTPA: comparison of plasma clearance techniques. J Nucl Med. 1987;28(30):372–7.PubMed Waller DG, Keast CM, Fleming JS, Ackery DM. Measurement of glomerular filtration rate with technetium-99m DTPA: comparison of plasma clearance techniques. J Nucl Med. 1987;28(30):372–7.PubMed
13.
Zurück zum Zitat Jodrell, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10(4):520–8.PubMed Jodrell, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10(4):520–8.PubMed
14.
Zurück zum Zitat Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med. 1988;84(6):1053–60.PubMedCrossRef Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med. 1988;84(6):1053–60.PubMedCrossRef
15.
Zurück zum Zitat Martin J, et al. Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients. Bull Cancer. 1998;85:631–6.PubMed Martin J, et al. Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients. Bull Cancer. 1998;85:631–6.PubMed
16.
Zurück zum Zitat Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9(10):1053–71.PubMedCrossRef Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9(10):1053–71.PubMedCrossRef
17.
Zurück zum Zitat Raj GV, Iasonos A, Herr H, Donat SM. Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J Clin Oncol. 2006;24(19):3095–100.PubMedCrossRef Raj GV, Iasonos A, Herr H, Donat SM. Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J Clin Oncol. 2006;24(19):3095–100.PubMedCrossRef
18.
Zurück zum Zitat Dobyan DC. Long-term consequences of cis-platinum-induced renal injury: a structural and functional study. Anat Rec. 1985;212(3):239–45.PubMedCrossRef Dobyan DC. Long-term consequences of cis-platinum-induced renal injury: a structural and functional study. Anat Rec. 1985;212(3):239–45.PubMedCrossRef
19.
Zurück zum Zitat Li, et al. Regulation of the creatine transporter by AMP-activated protein kinase in kidney epithelial cells. Am J Physiol Renal Physiol. 2010;299(1):F167–77.PubMedCrossRef Li, et al. Regulation of the creatine transporter by AMP-activated protein kinase in kidney epithelial cells. Am J Physiol Renal Physiol. 2010;299(1):F167–77.PubMedCrossRef
Metadaten
Titel
Accuracy of GFR estimation by the Cockroft and Gault, MDRD, and Wright equations in Oncology patients with renal impairment
verfasst von
O. O. Faluyi
S. P. Masinghe
R. L. Hayward
S. Clive
Publikationsdatum
01.06.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9824-0

Weitere Artikel der Ausgabe 2/2012

Medical Oncology 2/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.